According to the TLV, “The prices of medicines that have been on the market between 5 and 15 years...
Read moreThe aim of this trial is to increase capacity, with a goal of a 20% increase by 2023-24.
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreThe subscription-style payment model for antibiotics announced by NICE in April 2022 will be capped ...
Read moreThe Access Consortium is made up of regulatory authorities including the UK, Australia, Canada, Sing...
Read moreThe High Authority for Health (HAS) and National Agency for Drug Safety (ANSM) have published a prel...
Read moreWith respects to pricing and reimbursement, the societies reportedly call for the criteria that led ...
Read moreDurvalumab was previously made available to NHS patients in 2019 through the Cancer Drugs Fund (CDF)...
Read moreThe research looks at the benefits for 13 medicines across four treatment areas.
Read moreIntroduction As the most populous country in the world with 1.4 billion inhabitants, China has the p...
Read more